{"id":"abt-530","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4761843","moleculeType":"Unknown","molecularWeight":"704.93"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CCR2 is a G-protein coupled receptor expressed on monocytes and other immune cells that mediates their migration in response to chemokine signals. By blocking CCR2, ABT-530 reduces the infiltration of pro-inflammatory monocytes into inflamed tissues, thereby dampening inflammatory responses. This mechanism is being explored in conditions characterized by excessive monocyte-driven inflammation.","oneSentence":"ABT-530 is a selective inhibitor of the chemokine receptor CCR2 that reduces inflammatory monocyte recruitment to sites of inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:28:26.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory conditions (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT04903626","phase":"PHASE3","title":"Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-08-24","conditions":"Hepatitis C Virus (HCV)","enrollment":286},{"nctId":"NCT03067129","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Hepatitis C Virus (HCV)","enrollment":129},{"nctId":"NCT02939989","phase":"PHASE3","title":"Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-11-21","conditions":"Hepatitis C Virus Infection","enrollment":33},{"nctId":"NCT02966795","phase":"PHASE3","title":"A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-01-25","conditions":"Hepatitis C Virus (HCV)","enrollment":84},{"nctId":"NCT02640157","phase":"PHASE3","title":"A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Genotype 3 Hepatitis C Virus","enrollment":506},{"nctId":"NCT02243293","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09-19","conditions":"Chronic Hepatitis C, Hepatitis C Virus","enrollment":694},{"nctId":"NCT02707952","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-22","conditions":"Chronic Hepatitis C Virus, Hepatitis C Virus","enrollment":295},{"nctId":"NCT02723084","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-08","conditions":"Chronic Hepatitis C Virus, Hepatitis C Virus","enrollment":136},{"nctId":"NCT02640482","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":304},{"nctId":"NCT02604017","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":703},{"nctId":"NCT02636595","phase":"PHASE3","title":"The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11","conditions":"Hepatitis C Virus","enrollment":121},{"nctId":"NCT02738138","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-05-17","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":153},{"nctId":"NCT02692703","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-22","conditions":"Chronic Hepatitis C, HCV, Hepatitis C Virus","enrollment":100},{"nctId":"NCT02243280","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-08","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":174},{"nctId":"NCT02642432","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-07","conditions":"Hepatitis C Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis","enrollment":146},{"nctId":"NCT01995071","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":89},{"nctId":"NCT02441283","phase":"PHASE2, PHASE3","title":"A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06-22","conditions":"Hepatitis C","enrollment":384},{"nctId":"NCT03089944","phase":"PHASE3","title":"A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-28","conditions":"Hepatitis C Virus (HCV)","enrollment":343},{"nctId":"NCT03219216","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-06-06","conditions":"Hepatitis C Virus (HCV)","enrollment":100},{"nctId":"NCT03123965","phase":"","title":"Expanded Access to Glecaprevir/ Pibrentasvir","status":"APPROVED_FOR_MARKETING","sponsor":"AbbVie","startDate":"","conditions":"Hepatitis C Virus Infection","enrollment":""},{"nctId":"NCT03222583","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-04","conditions":"Hepatitis C Virus (HCV)","enrollment":546},{"nctId":"NCT03235349","phase":"PHASE3","title":"Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-09-29","conditions":"Hepatitis C Virus (HCV)","enrollment":160},{"nctId":"NCT03212521","phase":"PHASE3","title":"Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-07","conditions":"Hepatitis C Virus (HCV)","enrollment":230},{"nctId":"NCT03069365","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-28","conditions":"Hepatitis C Virus (HCV)","enrollment":101},{"nctId":"NCT02068222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-04","conditions":"Chronic Hepatitis C, Hepatitis C Virus","enrollment":10},{"nctId":"NCT02651194","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":104},{"nctId":"NCT02446717","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":141},{"nctId":"NCT02442258","phase":"PHASE1","title":"Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-03","conditions":"Renal Impairment","enrollment":46},{"nctId":"NCT02296905","phase":"PHASE1","title":"Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10","conditions":"Hepatic Impairment","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["pibrentasvir","Pibrentasvir"],"phase":"phase_2","status":"active","brandName":"ABT-530","genericName":"ABT-530","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-530 is a selective inhibitor of the chemokine receptor CCR2 that reduces inflammatory monocyte recruitment to sites of inflammation. Used for Inflammatory conditions (Phase 2 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}